These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21709210)

  • 1. Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease.
    Dhaun N; Johnston NR; Goddard J; Webb DJ
    Hypertension; 2011 Aug; 58(2):e11-2. PubMed ID: 21709210
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease.
    Dhaun N; MacIntyre IM; Kerr D; Melville V; Johnston NR; Haughie S; Goddard J; Webb DJ
    Hypertension; 2011 Apr; 57(4):772-9. PubMed ID: 21357275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.
    Dhaun N; Yuzugulen J; Kimmitt RA; Wood EG; Chariyavilaskul P; MacIntyre IM; Goddard J; Webb DJ; Corder R
    J Am Heart Assoc; 2015 Mar; 4(3):e001624. PubMed ID: 25801761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of uric acid correlate with decline of glomerular filtration rate in chronic kidney disease.
    Satirapoj B; Supasyndh O; Nata N; Phulsuksombuti D; Utennam D; Kanjanakul I; Choovichian P; Duangurai K
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S65-70. PubMed ID: 21280518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between hyperuricemia and chronic kidney disease.
    Ohno I
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1039-44. PubMed ID: 22132954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relief of chronic neuropathic pain through endothelin antagonism.
    Murphy DM; O'Callaghan DS; Gaine SP
    Am J Med; 2010 Mar; 123(3):e7. PubMed ID: 20193818
    [No Abstract]   [Full Text] [Related]  

  • 7. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
    Goddard J; Johnston NR; Hand MF; Cumming AD; Rabelink TJ; Rankin AJ; Webb DJ
    Circulation; 2004 Mar; 109(9):1186-93. PubMed ID: 14981006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes: Lowering serum uric acid levels to prevent kidney failure.
    Doria A; Krolewski AS
    Nat Rev Nephrol; 2011 Aug; 7(9):495-6. PubMed ID: 21808278
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
    Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
    Rayner BL; Trinder YA; Baines D; Isaacs S; Opie LH
    Am J Hypertens; 2006 Feb; 19(2):208-13. PubMed ID: 16448895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum uric acid levels and renal damage in hyperuricemic hypertensive patients treated with renin-angiotensin system blockers.
    Berni A; Boddi M; Fattori EB; Cecioni I; Berardino S; Montuschi F; Chiostri M; Poggesi L
    Am J Hypertens; 2010 Jun; 23(6):675-80. PubMed ID: 20203626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
    Fujimori S; Ooyama K; Ooyama H; Moromizato H
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter study of the association of serum uric acid, serum creatinine, and diuretic use in hypertensive patients.
    Lin CS; Hung YJ; Chen GY; Tzeng TF; Lee DY; Chen CY; Huang WP; Huang CH
    Int J Cardiol; 2011 May; 148(3):325-30. PubMed ID: 20053470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan.
    Lin CS; Lee WL; Hung YJ; Lee DY; Chen KF; Chi WC; Chang SC
    Int J Cardiol; 2012 Apr; 156(1):41-6. PubMed ID: 21095025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum uric acid and arterial stiffness in hypertensive chronic kidney disease patients: sex-specific variations.
    Elsurer R; Afsar B
    Blood Press Monit; 2014 Oct; 19(5):271-9. PubMed ID: 24892881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers].
    Mizuta E; Hamada T; Igawa O; Shigemasa C; Hisatome I
    Clin Calcium; 2010 Jan; 20(1):45-50. PubMed ID: 20048433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum uric acid and the risk of hypertension and chronic kidney disease.
    Feig DI
    Curr Opin Rheumatol; 2014 Mar; 26(2):176-85. PubMed ID: 24419747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial.
    Hart A; Jackson S; Kasiske BL; Mauer MS; Najafian B; Matas AJ; Spong R; Ibrahim HN
    Transplantation; 2014 May; 97(10):1066-71. PubMed ID: 24503762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.